Pharmacovigilance of malaria intermittent preventive treatment in infants coupled with routine immunizations in 6 African countries

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 1, 2012, Pages

  De Sousa, Alexandra ^a   Rabarijaona, Leon Paul ^a   Tenkorang, Ofori ^a,b   Inkoom, Ebenezer ^a   Ravelomanantena, Hantamalala V ^c   Njarasoa, Sabrina ^c   Whang, Jeremiah Nee ^b   Ndiaye, Jean Louis ^d   Ndiaye, Youssoupha ^e   Ndiaye, Mouhamed ^d   Sow, Doudou ^d   Akadiri, Guinoussa ^a   Hassan, Jacques ^a   Dicko, Alassane ^f   Sagara, Issaka ^f   Kubalalika, Prestor ^g   Mathanga, Don ^g   Bizuneh, Ketema ^a   Randriasamimanana, Jean Rene ^c   Recht, Judith ^a   Bjelic, Ivana ^a   Dodoo, Alexander ^b   more..

^a UNICEF   (United States)

^b UNIVERSITY OF GHANA   (Ghana)

^c Centre National de Pharmacovigilance   (Madagascar)

^d UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^e Senegal Ministry of Health   (Senegal)

^f UNIVERSITY OF BAMAKO   (Mali)

^g UNIVERSITY OF MALAWI   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; PYRIMETHAMINE PLUS SULFADOXINE; YELLOW FEVER VACCINE;

AFRICA; ARTICLE; COHORT ANALYSIS; CONVULSION; COUGHING; DERMATITIS; DIARRHEA; DIPHTHERIA; DRUG ERUPTION; DRUG FEVER; DRUG SURVEILLANCE PROGRAM; ENTERITIS; EXFOLIATIVE DERMATITIS; FEMALE; FOLLOW UP; HAEMOPHILUS INFECTION; HEPATITIS A; HEPATITIS B; HUMAN; HYPOCHROMIC MACULA; IMMUNIZATION; INFANT; INJECTION SITE REACTION; INTERMITTENT PREVENTIVE TREATMENT IN INFANTS; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; MEASLES; MONITORING; NAUSEA; NERVOUSNESS; PATHOLOGICAL CRYING; PERTUSSIS; PNEUMONIA; POLIOMYELITIS; PRIORITY JOURNAL; PRURITUS; REGISTER; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; STOMACH PAIN; TETANUS; VOMITING; WORLD HEALTH ORGANIZATION; YELLOW FEVER;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AFRICA; ANTIMALARIALS; DRUG COMBINATIONS; DRUG TOXICITY; FEMALE; HUMANS; IMMUNIZATION; INFANT; MALARIA; MALARIA VACCINES; MALE; PHARMACOVIGILANCE; PYRIMETHAMINE; SULFADOXINE;

EID: 84856891109     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir799     Document Type: Article

References (50)

1. Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health 2003; 8:488-506. (Pubitemid 36724013)
2. Menendez C, Bardaji A, Sigauque B, et al. Malaria prevention with IPTp during pregnancy reduces neonatal mortality. PLoS One 2010; 5:e9438.
3. Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009; 374:1533-42.
4. Manzi F, Hutton G, Schellenberg J, et al. From strategy development to routine implementation: the cost of intermittent preventive treatment in infants for malaria control. BMC Health Serv Res 2008; 8:165.
5. WHO. Interim report on IPTi with SP. In: IPTi, WACoSrtEviIr, ed. Report WACoSrtEviIrII. Geneva: World Health Organization, 2006.
6. Meyboom RH. Adverse reaction to drugs in children, experiences with "spontaneous monitoring" in the Netherlands. Bratisl Lek Listy 1991; 92:554-9.
7. Menniti-Ippolito G, Raschetti R, Da Cas R, Giaquinto C, Cantarutti L. Active monitoring of adverse drug reactions in children. Italian Paediatric Pharmacosurveillance Multicenter Group. Lancet 2000; 355:1613-14. (Pubitemid 30240508)
8. White NJ. Intermittent presumptive treatment for malaria. PLoS Med 2005; 2:e3.
9. Bjorkman A, Phillips-Howard PA. Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bull World Health Organ 1991; 69:297-304.
10. Morales-Olivas FJ, Martinez-Mir I, Ferrer JM, Rubio E, Palop V. Adverse drug reactions in children reported by means of the yellow card in Spain. J Clin Epidemiol 2000; 53:1076-80.
11. Stephenson T. Medicines for childrendthe last century and the next. Arch Dis Child 2001; 85:177-9. (Pubitemid 32822372)
12. Staedke SG, Mpimbaza A, Kamya MR, Nzarubara BK, Dorsey G, Rosenthal PJ. Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet 2004; 364:1950-7. (Pubitemid 39574598)
13. Rwagacondo CE, Karema C, Mugisha V, et al. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health 2004; 9:1091-8. (Pubitemid 39423087)
14. Breman JG, Egan A, Keusch GT. The intolerable burden of malaria: a new look at the numbers. Am J Trop Med Hyg 2001; 64:iv-vii. (Pubitemid 32552565)
15. Rafael ME, Taylor T, Magill A, Lim YW, Girosi F, Allan R. Reducing the burden of childhood malaria in Africa: the role of improved diagnostics. Nature 2006; 444(Suppl 1):39-48.
16. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995; 102:1669-76.
17. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010; 5:39.
18. Sturchler D, Mittelholzer ML, Kerr L. How frequent are notified severe cutaneous adverse reactions to Fansidar? Drug Saf 1993; 8:160-8. (Pubitemid 23075565)
19. Eriksen J, Nsimba SE, Minzi OM, et al. Adoption of the new antimalarial drug policy in Tanzaniada cross-sectional study in the community. Trop Med Int Health 2005; 10:1038-46. (Pubitemid 41445069)
20. Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 1990; 83:82-5. (Pubitemid 20159350)
21. Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC. Severe cutaneous reactions among American travelers using pyrimethamine- sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35:451-8. (Pubitemid 16089959)
22. Hellgren U, Rombo L, Berg B, Carlson J, Wiholm BE. Adverse reactions to sulphadoxine-pyrimethamine in Swedish travellers: implications for prophylaxis. Br Med J (Clin Res Ed) 1987; 295:365-6. (Pubitemid 17125762)
23. Colebunders R, Izaley L, Bila K, et al. Cutaneous reactions to trimethoprim-sulfamethoxazole in African patients with the acquired immunodeficiency syndrome. Ann Intern Med 1987; 107:599-600. (Pubitemid 17149785)
24. Wolkenstein P, Carriere V, Charue D, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5:255-8.
25. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600-7.
26. Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics 2007; 120:e1082-96. (Pubitemid 47549574)
27. Gimnig JE, MacArthur JR, MBang'ombe M, et al. Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprimsulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg 2006; 74:738-43. (Pubitemid 46774388)
28. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004; 27:25-61. (Pubitemid 38186936)
29. Bergoend H, Loffler A, Amar R, Maleville J. Cutaneous reactions appearing during the mass prophylaxis of cerebrospinal meningitis with a long-delayed action sulfonamide (apropos of 997 cases). Ann Dermatol Syphiligr (Paris) 1968; 95:481-90.
30. FANSIDAR brand of sulfadoxine and pyrimethamine tablets-complete product information. In: Roche, ed. Basel, Switzerland: Roche Pharmaceuticals, 2004.
31. Pirmohamed M, Arbuckle JB, Bowman CE, et al. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007; 9:1661-91.
32. Pirmohamed M, Atuah KN, Dodoo AN, Winstanley P. Pharmacovigilance in developing countries. BMJ 2007; 335:462. (Pubitemid 47401595)
33. Hernborg A. Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique. Lancet 1985; 2:1072-3. (Pubitemid 16206775)
34. Taylor GM. Stevens-Johnson syndrome following the use of an ultralong-acting sulphonamide. S Afr Med J 1968; 42:501-3.
35. Mehta U, Durrheim D, Mabuza A, Blumberg L, Allen E, Barnes KI. Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa. Drug Saf 2007; 30:899-910. (Pubitemid 47481445)
36. Steffen R, Somaini B. Severe cutaneous adverse reactions to sulfadoxinepyrimethamine in Switzerland. Lancet 1986; 1:610. (Pubitemid 16138395)
37. WHO. Report of the technical consultation on intermittent preventive treatment in infants (IPTi). Geneva: WHO, 2009.
38. de Sousa A, Salama P, Chopra M. Implementing intermittent preventive treatment in infants. Lancet 2010; 375:121.
39. Chandramohan D, Owusu-Agyei S, Carneiro I, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 2005; 331:727-33. (Pubitemid 41414939)
40. Rabarijaona LP, Randrianarivelojosia M, Raharimalala LA, et al. Longitudinal survey of malaria morbidity over 10 years in Saharevo (Madagascar): further lessons for strengthening malaria control. Malar J 2009; 8:190.
41. UNICEF. ChildInfo. Statistics by area/HIV/AIDS. http://www.childinfo. org/hiv-aids-prevalence.php. Accessed 20 June 2011.
42. UNICEF. Childinfo. Statistics by area/Child survival and health. http://www.childinfo.org/immunization-countrydata.php. Accessed 20 June 2011.
43. Coulter DM. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance. Pharmacoepidemiol Drug Saf 2000; 9:273-80.
44. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10:93-102. (Pubitemid 24045719)
45. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17:374-89. (Pubitemid 28017927)
46. WHO. Supplementary information on vaccine safety. Part 2: Background rates of adverse events following immunization. Geneva, World Health Organisation, 2000.
47. Dodoo AN, Renner L, van Grootheest AC, et al. Safety monitoring of a new pentavalent vaccine in the expanded programme on immunisation in Ghana. Drug Saf 2007; 30:347-56. (Pubitemid 46624533)
48. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45: 1-35.
49. UNICEF. Ghana multiple indicator cluster survey, 2006. www.childinfo. org/files/MICS3-Ghana-FinalReport-2006-Eng.pdf. Accessed 20 June 2011.
50. Madagascar: DHS, 2003-04-final report. http://www.measuredhs.com/pubs/ pub-details.cfm?ID5491. Accessed 10 February 2009.